Xi’an Salus Nutra Inc Established in 2015 and located in Hi-Tech industrial Zone in xi’an city, which is the most advanced area in northwest china . Salus Nutra is a professional company specialized in natural plant extracts, collagen and high technology chemical API field in scientific research, producing and marketing.

Our products are mainly used in healthcare supplement, chemicals ,pharmaceutical, cosmetics and food additives. We are also engaged in supplying customization OEM service to help customers choose their right ingredients and develop their broad markets .

Our factory is located in BaoJi ,shaanxi province, it coveries an area of XX acres and equips with 2 standard production workshops meet with State Health Standards ,meanwhile employs more than 500 people with well-educated, including undergraduate, Postgraduate and some technical persons with rich experience.

Salus is committed to supplying safe, pure and healthy products that meet the high expectations of our customers. Experienced and dedicated members of the Quality and food safety Department work to provide in-depth analyses, testing and monitoring of our products, during and after the manufacturing processes and ensure the quality and safety according to the highest standards.

We are based on the honest and mutual benefits, rely on the reliable quality and best after-sale service to make good reputations both online and offline. Now it shares a great popularities from the customers at overseas. Our primary goal aims to solve customer problems through research & development & technical service .

If you have any doubts or confusion, YES, Salus will present the exactly right answer.

High Quality BIBW 2992

It is the second generation of high efficiency double irreversibility of tyrosine kinase inhibitors.The treatment for it, and as a tyrosine kinase inhibitor, single inhibiting EGFR, BIBW2992 while inhibiting EGFR and its ehrs - 2 two receptors.Gay royal hospital medical school in London, James Sr on various kinds of solid tumor patients were studied, Ⅰ period clinical studies have shown that patients with EGFR mutations of NSCLC can be obtained encouraging results, 20% of patients get sustainable PR (2 female and male 1), 2 cases showed EGFR exon 19 deletions, the mutation type found in women, non-smokers and adenocarcinoma patients.BIBW2992 oral 50 mg were well tolerated.BIBW2992 Ⅱ period clinical study showed that patients with EGFR mutations of NSCLC, the first generation of tyrosine kinase inhibitors, resistant BIBW2992 antineoplastic activity of its potential.

Name:   BIBW 2992
Synonyms N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
Molecular Formula C24H25ClFN5O3
Molecular Weight 485.94

CAS Registry Number 439081-18-2